Difference between revisions of "De Jesus-Acosta A, et al. Invest. N. Drugs (2014) cited as Ref 586 in DOI: 10.1038/s41392-020-0110-5 (Q9849)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 32, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma, #quickstatements; #temporary_batch_1590010982689) |
||
| Property / title | |||
| + | A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma (English) | ||
| Property / title: A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma (English) / rank | |||
| + | Normal rank | ||
Revision as of 22:04, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
De Jesus-Acosta A, et al. Invest. N. Drugs (2014) cited as Ref 586 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
De Jesus-Acosta A
0 references
2014
0 references
Invest. N. Drugs
0 references
32
0 references
A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma (English)
0 references
